Research graph
References from Rethinking cardiovascular risk stratification in TKI-treated chronic myeloid leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Chronic myeloid Leukemia: a review
10.1001/jama.2025.0220 · 2025 · External reference
Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome
10.1111/ejh.12367 · 2015 · External reference
Cardiovascular disease in patients with chronic myeloid leukemia
2025 · External reference
Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis
10.1001/jamaoncol.2015.5932 · 2016 · External reference
The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
10.1186/s40959-025-00366-x · 2025 · External reference
Incidence of cardiovascular events and carotid artery USG abnormalities in chronic myeloid leukemia patients on Nilotinib therapy: a 20-year single-center study
10.1016/j.clml.2025.04.015 · 2025 · External reference
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis
10.1182/bloodadvances.2019001329 · 2020 · External reference
Cardiovascular risk in chronic myeloid leukaemia: a multidisciplinary consensus on screening and management
10.1111/ejh.13983 · 2023 · External reference
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
10.1111/bjh.16733 · 2021 · External reference
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
10.1182/blood-2016-09-739086 · 2018 · External reference
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)
10.1093/eurheartj/ehac244 · 2022 · External reference
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
10.1007/s00277-023-05556-0 · 2024 · External reference
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
10.1038/leu.2013.70 · 2013 · External reference
2024 ESC guidelines for the management of peripheral arterial and aortic diseases
10.1093/eurheartj/ehae179 · 2024 · External reference
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
10.1093/eurheartj/ehab309 · 2021 · External reference
Epidemiology of chronic myeloid leukaemia: an update
10.1007/s00277-015-2314-2 · 2015 · External reference
Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010
10.4103/0971-5851.123712 · 2013 · External reference
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
10.1186/s40959-024-00245-x · 2024 · External reference
Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care
10.1161/atvbaha.119.313353 · 2020 · External reference
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia
10.1016/j.jacc.2025.11.016 · 2026 · External reference
Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study
10.1016/j.jacc.2015.12.056 · 2016 · External reference
Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7/8
10.1016/j.jacc.2021.05.011 · 2021 · External reference
Duplex ultrasound for diagnosing symptomatic carotid stenosis in the extracranial segments
2022 · External reference
Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial
10.1016/s0140-6736(18)32818-6 · 2019 · External reference
Coronary CT angiography and 5-year risk of myocardial infarction
10.1056/nejmoa1805971 · 2018 · External reference
Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial
10.1056/nejmoa2208681 · 2022 · External reference
